BLRX - BioLineRx (BLRX) shares rocket 73% on positive Motixafortide data in multiple myeloma

BioLineRx (BLRX) soars 73% premarket in reaction to the announcement of positive top-line results from Phase 3 GENESIS trial evaluating Motixafortide, in combination with granulocyte colony stimulating factor (G-CSF, the standard of care in this indication), for hematopoietic stem-cell mobilization for autologous bone marrow transplantation in multiple myeloma patients.The primary endpoint of the study demonstrated a 4.9-fold increase (70.0% vs 14.3%; difference 54.6%; 95% CI 39.7-69.5%; p<0.0001) in the proportion of patients in the treatment arm, as compared to the control arm mobilizing ? 6M CD34+ cells/kg in up to two apheresis sessions, and after only one administration of Motixafortide. This translates to an odds-ratio of 12.9.The study also achieved its main secondary endpoint, demonstrating a 14.1-fold increase in the proportion of patients in the treatment arm, as compared to the control arm, who mobilized ? 6M CD34+ cells/kg in just one apheresis session and translating to an odds-ratio of 56.0.Other important

For further details see:

BioLineRx (BLRX) shares rocket 73% on positive Motixafortide data in multiple myeloma